Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-07248144 + PF-07220060 + fulvestrant
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
PF-07248144 + PF-07220060 + fulvestrant is a triple combination investigational regimen being studied in advanced or metastatic solid tumors, most notably in hormone receptor (HR)-positive, HER2-negative breast cancer. PF-07248144 is a small molecule inhibitor targeting epigenetic regulation, specifically the KAT6A/B histone acetyltransferases. PF-07220060 is an oral CDK4/6 inhibitor, designed to block cell cycle progression in cancer cells by inhibiting cyclin-dependent kinase 4/6 activity. Fulvestrant is a selective estrogen receptor degrader (SERD) that binds, blocks, and degrades the estrogen receptor, thereby antagonizing estradiol-driven tumor growth. This combination is being developed by Pfizer for dose escalation and expansion cohorts in post-CDK4/6 inhibitor settings[1][3][7].
- Other names
- fulvestrant
02
Targets
ER (Estrogen receptor)KAT6A (Lysine acetyltransferase 6A)CDK4 (Cyclin-dependent kinase 4)KAT6B (Histone acetyltransferase KAT6B)
Beyond the preview
Go deeper on PF-07248144 + PF-07220060 + fulvestrant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-07248144 + PF-07220060 + fulvestrant.